Abstract

Introduction While hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreduction surgery (CRS) has been shown to improve patient survival and disease-free progression in peritoneal carcinoma (PC) patients, the procedure relates to a high postoperative infection rate. Herein, we report the bacterial and fungal infections after CRS and HIPEC from a single institution in Saudi Arabia. Patients and Methods A prospective observational study was conducted on 38 patients with PC selected for CRS/HIPEC procedure between 2012 and 2015 in our centre. Results Postoperative bacterial and fungal infection within 100 days was 42.2%, bacterial infection was reported always, and fungal infection was reported in 5 (13.2%) cases. Infections from the surgical site were considered the most common infection site. Multidrug-resistant extended-spectrum beta-lactamase (ESBL) Escherichia coli was the most frequent isolate, followed by multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Lower preoperative albumin and a prolonged preoperative activated partial thromboplastin time (APTT) are associated with postoperative infections, while a prolonged preoperative hospital stay (hazard ratio (HR) = 1.064; confidence interval (CI) = 1.002–1.112; P=0.042) and more intraoperative blood loss (>10%) (HR = 3.919; 95% CI = 1.024–14.995; P=0.046) were independent risk factors for postoperative infections. Three cases died during the follow-up period; all were due to infection. Discussion The infection rate in our centre compared to previous studies of comparable patients was matching. Effective management of postoperative infections should be considered, and identified risk factors in this study can help to focus on effective prevention and treatment strategies.

Highlights

  • While hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreduction surgery (CRS) has been shown to improve patient survival and disease-free progression in peritoneal carcinoma (PC) patients, the procedure relates to a high postoperative infection rate

  • Mucinous adenocarcinoma (15 (39.5%)) was the most commonly encountered histopathology; the colorectal tumour was the primary site of tumour in 20 (52.6%) patients

  • CRS and HIPEC are a promising therapeutic modality for PC patients; postoperative infections still represent the main cause for mortality, prolonged hospital stay, and healthcare costs in those patients [8, 9, 24]

Read more

Summary

Introduction

While hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreduction surgery (CRS) has been shown to improve patient survival and disease-free progression in peritoneal carcinoma (PC) patients, the procedure relates to a high postoperative infection rate. A prospective observational study was conducted on 38 patients with PC selected for CRS/ HIPEC procedure between 2012 and 2015 in our centre. Effective management of postoperative infections should be considered, and identified risk factors in this study can help to focus on effective prevention and treatment strategies. Cytoreduction surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is being used more and more in selected PC patients and offers a promising. HIPEC after CRS rests on surgical removal of the primary tumour and applying a concentrated and heated chemotherapeutic agent in the peritoneal cavity. Mitomycin C (MMC) and oxaliplatin are both suitable as intraperitoneal chemotherapeutic agents in HIPEC for PC, and both showed encouraging survival results [7]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call